JNK acts as a molecular brake of the CDC73 positive feedback loop to modulate osteosarcoma malignant progression via UBR5

IF 9.1 1区 医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY
Dingji Li, Xinchen Wang, Huigen Luo, Hua Tu, Lili Hao, IoHong Lei, Renjie Hu, Pengchao Zheng, Yuhan Shi, Jianbo Sun, Minying Zhu, Chengnong Guan, Baoshan Xu
{"title":"JNK acts as a molecular brake of the CDC73 positive feedback loop to modulate osteosarcoma malignant progression via UBR5","authors":"Dingji Li, Xinchen Wang, Huigen Luo, Hua Tu, Lili Hao, IoHong Lei, Renjie Hu, Pengchao Zheng, Yuhan Shi, Jianbo Sun, Minying Zhu, Chengnong Guan, Baoshan Xu","doi":"10.1038/s41388-026-03978-4","DOIUrl":null,"url":null,"abstract":"CDC73 is a well-characterized tumor suppressor regulated by stress stimuli, governing progression of diverse human malignancies. Although previous studies have shown that E3 ubiquitin ligase UBR5 drives CDC73 ubiquitination and degradation to modulate tumorigenesis, the mechanisms by which stress-responsive pathways regulate UBR5-mediated CDC73 inactivation and transcriptional reprogramming remain elusive. Here, via integrated analyses of public datasets, multi-omics profiling (assay for transposase-accessible chromatin with sequencing [ATAC-seq], cleavage under targets and tagmentation [CUT&Tag], mRNA sequencing [mRNA-seq]), in vitro/in vivo assays, and molecular approaches including co-immunoprecipitation (Co-IP) and molecular docking, we demonstrate that UBR5 depletion profoundly alters chromatin accessibility and genome-wide transcriptional profiles in a CDC73-dependent manner. UBR5 ablation markedly suppresses osteosarcoma malignant phenotypes in cultured cells and xenograft models, with these effects fully rescued by concurrent CDC73 silencing. Mechanistically, we identify the JNK cascade as the critical upstream regulator: JNK activation sustains CDC73 stability by antagonizing UBR5-mediated CDC73 polyubiquitination, and map Lys257 as the key residue for UBR5-dependent CDC73 ubiquitination and degradation. Collectively, our findings define a novel JNK-dependent UBR5-CDC73 axis that acts as a molecular brake of the CDC73 positive feedback loop to orchestrate transcriptional programs, providing new mechanistic insights into CDC73 post-translational regulation in tumorigenesis and promising therapeutic targets for CDC73-dysregulated diseases.","PeriodicalId":19524,"journal":{"name":"Oncogene","volume":"45 43","pages":"4689-4702"},"PeriodicalIF":9.1000,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncogene","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/s41388-026-03978-4","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

CDC73 is a well-characterized tumor suppressor regulated by stress stimuli, governing progression of diverse human malignancies. Although previous studies have shown that E3 ubiquitin ligase UBR5 drives CDC73 ubiquitination and degradation to modulate tumorigenesis, the mechanisms by which stress-responsive pathways regulate UBR5-mediated CDC73 inactivation and transcriptional reprogramming remain elusive. Here, via integrated analyses of public datasets, multi-omics profiling (assay for transposase-accessible chromatin with sequencing [ATAC-seq], cleavage under targets and tagmentation [CUT&Tag], mRNA sequencing [mRNA-seq]), in vitro/in vivo assays, and molecular approaches including co-immunoprecipitation (Co-IP) and molecular docking, we demonstrate that UBR5 depletion profoundly alters chromatin accessibility and genome-wide transcriptional profiles in a CDC73-dependent manner. UBR5 ablation markedly suppresses osteosarcoma malignant phenotypes in cultured cells and xenograft models, with these effects fully rescued by concurrent CDC73 silencing. Mechanistically, we identify the JNK cascade as the critical upstream regulator: JNK activation sustains CDC73 stability by antagonizing UBR5-mediated CDC73 polyubiquitination, and map Lys257 as the key residue for UBR5-dependent CDC73 ubiquitination and degradation. Collectively, our findings define a novel JNK-dependent UBR5-CDC73 axis that acts as a molecular brake of the CDC73 positive feedback loop to orchestrate transcriptional programs, providing new mechanistic insights into CDC73 post-translational regulation in tumorigenesis and promising therapeutic targets for CDC73-dysregulated diseases.
JNK作为CDC73正反馈回路的分子制动器,通过UBR5调节骨肉瘤的恶性进展。
CDC73是一种具有良好特征的肿瘤抑制因子,受应激刺激调节,控制多种人类恶性肿瘤的进展。虽然先前的研究表明E3泛素连接酶UBR5驱动CDC73泛素化和降解来调节肿瘤发生,但应激反应途径调节UBR5介导的CDC73失活和转录重编程的机制尚不清楚。本文通过对公共数据集、多组学分析(转座酶可及染色质测序[ATAC-seq]、靶标切割和标记[CUT&Tag]、mRNA测序[mRNA-seq])、体外/体内分析以及包括共免疫沉淀(Co-IP)和分子对接在内的分子方法的综合分析,我们证明了UBR5缺失以cdc73依赖的方式深刻地改变了染色质可及性和全基因组转录谱。UBR5消融术在培养细胞和异种移植物模型中显著抑制骨肉瘤的恶性表型,同时CDC73沉默完全恢复了这些作用。在机制上,我们确定JNK级联是关键的上游调节因子:JNK激活通过拮抗ubr5介导的CDC73泛素化来维持CDC73的稳定性,并将Lys257定位为ubr5依赖性CDC73泛素化和降解的关键残基。总的来说,我们的研究结果定义了一种新的jnk依赖性UBR5-CDC73轴,它作为CDC73正反馈回路的分子制动器来协调转录程序,为CDC73在肿瘤发生中的翻译后调控提供了新的机制见解,并为CDC73失调疾病的治疗靶点提供了希望。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Oncogene
Oncogene 医学-生化与分子生物学
CiteScore
15.30
自引率
1.20%
发文量
404
审稿时长
1 months
期刊介绍: Oncogene is dedicated to advancing our understanding of cancer processes through the publication of exceptional research. The journal seeks to disseminate work that challenges conventional theories and contributes to establishing new paradigms in the etio-pathogenesis, diagnosis, treatment, or prevention of cancers. Emphasis is placed on research shedding light on processes driving metastatic spread and providing crucial insights into cancer biology beyond existing knowledge. Areas covered include the cellular and molecular biology of cancer, resistance to cancer therapies, and the development of improved approaches to enhance survival. Oncogene spans the spectrum of cancer biology, from fundamental and theoretical work to translational, applied, and clinical research, including early and late Phase clinical trials, particularly those with biologic and translational endpoints.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书